1
|
Fujihara C, Murakami K, Magi S, Motooka D, Nantakeeratipat T, Canela A, Tanaka RJ, Okada M, Murakami S. Omics-Based Mathematical Modeling Unveils Pathogenesis of Periodontitis in an Experimental Murine Model. J Dent Res 2023; 102:1468-1477. [PMID: 37800405 DOI: 10.1177/00220345231196530] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/07/2023] Open
Abstract
Periodontitis is a multifactorial disease that progresses via dynamic interaction between bacterial and host-derived genetic factors. The recent trend of omics analyses has discovered many periodontitis-related risk factors. However, how much the individual factor affects the pathogenesis of periodontitis is still unknown. This article aims to identify multiple key factors related to the pathogenesis of periodontitis and quantitatively predict the influence of each factor on alveolar bone resorption by omics analysis and mathematical modeling. First, we induced periodontitis in mice (n = 3 or 4 at each time point) by tooth ligation. Next, we assessed alveolar bone resorption by micro-computed tomography, alterations in the gene expression by RNA sequencing, and the microbiome of the gingivae by 16S ribosomal RNA sequencing during disease pathogenesis. Omics data analysis identified key players (bacteria and molecules) involved in the pathogenesis of periodontitis. We then constructed a mathematical model of the pathogenesis of periodontitis by employing ordinary differential equations that described the dynamic regulatory interplay between the key players and predicted the alveolar bone integrity as output. Finally, we estimated the model parameters using our dynamic experimental data and validated the model prediction of influence on alveolar bone resorption by in vivo experiments. The model predictions and experimental results revealed that monocyte recruitment induced by bacteria-mediated Toll-like receptor activation was the principal reaction regulating alveolar bone resorption in a periodontitis condition. On the other hand, osteoblast-mediated osteoclast differentiation had less impact on bone integrity in a periodontitis condition.
Collapse
Affiliation(s)
- C Fujihara
- Department of Periodontology and Regenerative Dentistry, Osaka University Graduate School of Dentistry, Suita, Osaka, Japan
| | - K Murakami
- Laboratory of Cell Systems, Institute for Protein Research, Osaka University, Suita, Osaka, Japan
| | - S Magi
- Department of Physiology, Division of Cell Physiology, Faculty of Medicine, Toho University, Ota-ku, Tokyo, Japan
| | - D Motooka
- Genome Information Research Center, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan
| | - T Nantakeeratipat
- Department of Periodontology and Regenerative Dentistry, Osaka University Graduate School of Dentistry, Suita, Osaka, Japan
- Department of Conservative Dentistry and Prothodontics, Faculty of Dentistry, Srinakharinwirot University, Bangkok, Thailand
| | - A Canela
- The Hakubi Center for Advanced Research, Radiation Biology Center, Graduate School of Biostudies, Kyoto University, Kyoto, Japan
| | - R J Tanaka
- Department of Bioengineering, Imperial College London, London, UK
| | - M Okada
- Laboratory of Cell Systems, Institute for Protein Research, Osaka University, Suita, Osaka, Japan
- Human Metaverse Medicine (WPI-PRIMe), Osaka University, Suita, Osaka, Japan
| | - S Murakami
- Department of Periodontology and Regenerative Dentistry, Osaka University Graduate School of Dentistry, Suita, Osaka, Japan
| |
Collapse
|
2
|
Miao H, Zhang TT, Li HX, Fabbris G, Said AH, Tartaglia R, Yilmaz T, Vescovo E, Yin JX, Murakami S, Feng XL, Jiang K, Wu XL, Wang AF, Okamoto S, Wang YL, Lee HN. Signature of spin-phonon coupling driven charge density wave in a kagome magnet. Nat Commun 2023; 14:6183. [PMID: 37793998 PMCID: PMC10550957 DOI: 10.1038/s41467-023-41957-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2023] [Accepted: 09/21/2023] [Indexed: 10/06/2023] Open
Abstract
The intertwining between spin, charge, and lattice degrees of freedom can give rise to unusual macroscopic quantum states, including high-temperature superconductivity and quantum anomalous Hall effects. Recently, a charge density wave (CDW) has been observed in the kagome antiferromagnet FeGe, indicative of possible intertwining physics. An outstanding question is that whether magnetic correlation is fundamental for the spontaneous spatial symmetry breaking orders. Here, utilizing elastic and high-resolution inelastic x-ray scattering, we observe a c-axis superlattice vector that coexists with the 2[Formula: see text]2[Formula: see text]1 CDW vectors in the kagome plane. Most interestingly, between the magnetic and CDW transition temperatures, the phonon dynamical structure factor shows a giant phonon-energy hardening and a substantial phonon linewidth broadening near the c-axis wavevectors, both signaling the spin-phonon coupling. By first principles and model calculations, we show that both the static spin polarization and dynamic spin excitations intertwine with the phonon to drive the spatial symmetry breaking in FeGe.
Collapse
Affiliation(s)
- H Miao
- Materials Science and Technology Division, Oak Ridge National Laboratory, Oak Ridge, TN, USA.
| | - T T Zhang
- Department of Physics, Tokyo Institute of Technology, Okayama, Meguro-ku, Tokyo, Japan
| | - H X Li
- Materials Science and Technology Division, Oak Ridge National Laboratory, Oak Ridge, TN, USA
- Advanced Materials Thrust, The Hong Kong University of Science and Technology (Guangzhou), Guangzhou, China
| | - G Fabbris
- Advanced Photon Source, Argonne National Laboratory, Argonne, IL, USA
| | - A H Said
- Advanced Photon Source, Argonne National Laboratory, Argonne, IL, USA
| | - R Tartaglia
- Advanced Photon Source, Argonne National Laboratory, Argonne, IL, USA
- "Gleb Wataghin" Institute of Physics, University of Campinas, Campinas, São Paulo, Brazil
| | - T Yilmaz
- National Synchrotron Light Source II, Brookhaven National Laboratory, Upton, New York, USA
| | - E Vescovo
- National Synchrotron Light Source II, Brookhaven National Laboratory, Upton, New York, USA
| | - J-X Yin
- Laboratory for Quantum Emergence, Department of Physics, Southern University of Science and Technology, Shenzhen, China
| | - S Murakami
- Department of Physics, Tokyo Institute of Technology, Okayama, Meguro-ku, Tokyo, Japan
| | - X L Feng
- Beijing National Laboratory for Condensed Matter Physics, and Institute of Physics, Chinese Academy of Sciences, Beijing, China
| | - K Jiang
- Beijing National Laboratory for Condensed Matter Physics, and Institute of Physics, Chinese Academy of Sciences, Beijing, China
| | - X L Wu
- Low Temperature Physics Laboratory, College of Physics and Center of Quantum Materials and Devices, Chongqing University, Chongqing, China
| | - A F Wang
- Low Temperature Physics Laboratory, College of Physics and Center of Quantum Materials and Devices, Chongqing University, Chongqing, China.
| | - S Okamoto
- Materials Science and Technology Division, Oak Ridge National Laboratory, Oak Ridge, TN, USA.
| | - Y L Wang
- School of Emerging Technology, University of Science and Technology of China, Hefei, Anhui, China.
| | - H N Lee
- Materials Science and Technology Division, Oak Ridge National Laboratory, Oak Ridge, TN, USA
| |
Collapse
|
3
|
Yamaguchi T, Yamamoto Y, Egashira K, Sato A, Kondo Y, Saiki S, Kimura M, Chikazawa T, Yamamoto Y, Ishigami A, Murakami S. Oxidative Stress Inhibits Endotoxin Tolerance and May Affect Periodontitis. J Dent Res 2023; 102:331-339. [PMID: 36529984 DOI: 10.1177/00220345221138523] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
Periodontal disease is caused by dysbiosis of the dental biofilm and the host inflammatory response. Various pathogenic factors, such as proteases and lipopolysaccharides (LPSs) produced by bacteria, are involved in disease progression. Endotoxin tolerance is a function of myeloid cells, which sustain inflammation and promote tissue regeneration upon prolonged stimulation by endotoxins such as LPS. The role of endotoxin tolerance is gaining attention in various chronic inflammatory diseases, but its role in periodontal disease remains elusive. Oxidative stress, one of the major risk factors for periodontal disease, promotes disease progression through various mechanisms, of which only some are known. The effect of oxidative stress on endotoxin tolerance has not yet been studied, and we postulated that endotoxin tolerance regulation may be an additional mechanism through which oxidative stress influences periodontal disease. This study aimed to reveal the effect of oxidative stress on endotoxin tolerance and that of endotoxin tolerance on periodontitis progression. The effect of oxidative stress on endotoxin tolerance was analyzed in vitro using peritoneal macrophages of mice and hydrogen peroxide (H2O2). The results showed that oxidative stress inhibits endotoxin tolerance induced by Porphyromonas gingivalis LPS in macrophages, at least partially, by downregulating LPS-elicited negative regulators of Toll-like receptor (TLR) signaling. A novel oxidative stress mouse model was established using SMP30KO mice incapable of ascorbate biosynthesis. Using this model, we revealed that oxidative stress impairs endotoxin tolerance potential in macrophages in vivo. Furthermore, gingival expression of endotoxin tolerance-related genes and TLR signaling negative regulators was decreased, and symptoms of ligature-induced periodontitis were aggravated in the oxidative stress mouse model. Our findings suggest that oxidative stress may contribute to periodontitis progression through endotoxin tolerance inhibition.
Collapse
Affiliation(s)
- T Yamaguchi
- R&D Headquarters, LION Corporation, Tokyo, Japan.,Department of Periodontology, Osaka University Graduate School of Dentistry, Osaka, Japan
| | - Y Yamamoto
- R&D Headquarters, LION Corporation, Tokyo, Japan
| | - K Egashira
- R&D Headquarters, LION Corporation, Tokyo, Japan
| | - A Sato
- Molecular Regulation of Aging, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan
| | - Y Kondo
- Molecular Regulation of Aging, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan.,Faculty of Human Sciences, Waseda University, Tokyo, Japan
| | - S Saiki
- R&D Headquarters, LION Corporation, Tokyo, Japan
| | - M Kimura
- R&D Headquarters, LION Corporation, Tokyo, Japan
| | - T Chikazawa
- R&D Headquarters, LION Corporation, Tokyo, Japan
| | - Y Yamamoto
- R&D Headquarters, LION Corporation, Tokyo, Japan
| | - A Ishigami
- Molecular Regulation of Aging, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan
| | - S Murakami
- Department of Periodontology, Osaka University Graduate School of Dentistry, Osaka, Japan
| |
Collapse
|
4
|
Tamiya M, Goto Y, Kenmotsu H, Kurata T, Murakami S, Yanagitani N, Taniguchi H, Kuyama S, Shimizu J, Yokoyama T, Shimada N, T. M, Tamiya A, Uchiyama A, Imaizumi K, Takahama T, Nishio M, Hayashi H, Shiraiwa N, Okura M, Kikkawa H, Thomaidou D, Kato T. EP08.02-115 A Retrospective, Multicenter, Observational Study to Evaluate Outcomes With Lorlatinib After Alectinib in ALK+ NSCLC in Japan. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.798] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
5
|
Okuma Y, Nomura S, Ninomiya K, Yamaguchi H, Murakami S, Kogure Y, Harada D, Okishio K, Okamoto H, Goto Y. 1186TiP EPONA, efficacy of osimertinib with platinum and pemetrexed in EGFR mutant non-small cell lung cancer patients bearing CNS metastasis, and have systemic progression but stable intracranial disease on OsimertiNib resistAnce (TORG 1938). Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1309] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
6
|
Shinada K, Murakami S, Katakura S, Usio R, Kondo T, Kato T, Yokose T, Kasajima R, Miyagi Y, Saito H. EP11.01-008 Discrepancy in MET Exon 14 Skipping Mutation Measurement Between ArcherMET and Oncomine Dx Target Test System. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.905] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
7
|
Iwayama T, Bhongsatiern P, Takedachi M, Murakami S. Matrix Vesicle-Mediated Mineralization and Potential Applications. J Dent Res 2022; 101:1554-1562. [PMID: 35722955 DOI: 10.1177/00220345221103145] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Hard tissues, including the bones and teeth, are a fundamental part of the body, and their formation and homeostasis are critically regulated by matrix vesicle-mediated mineralization. Matrix vesicles have been studied for 50 y since they were first observed using electron microscopy. However, research progress has been hampered by various technical barriers. Recently, there have been great advancements in our understanding of the intracellular biosynthesis of matrix vesicles. Mitochondria and lysosomes are now considered key players in matrix vesicle formation. The involvement of mitophagy, mitochondrial-derived vesicles, and mitochondria-lysosome interaction have been suggested as potential detailed mechanisms of the intracellular pathway of matrix vesicles. Their main secretion pathway may be exocytosis, in addition to the traditionally understood mechanism of budding from the outer plasma membrane. This basic knowledge of matrix vesicles should be strengthened by novel nano-level microscopic technologies, together with basic cell biologies, such as autophagy and interorganelle interactions. In the field of tissue regeneration, extracellular vesicles such as exosomes are gaining interest as promising tools in cell-free bone and periodontal regenerative therapy. Matrix vesicles, which are recognized as a special type of extracellular vesicles, could be another potential alternative. In this review, we outline the recent significant progress in the process of matrix vesicle-mediated mineralization and the potential clinical applications of matrix vesicles for tissue regeneration.
Collapse
Affiliation(s)
- T Iwayama
- Department of Periodontology, Osaka University Graduate School of Dentistry, Suita, Osaka, Japan
| | - P Bhongsatiern
- Department of Periodontology, Osaka University Graduate School of Dentistry, Suita, Osaka, Japan
| | - M Takedachi
- Department of Periodontology, Osaka University Graduate School of Dentistry, Suita, Osaka, Japan
| | - S Murakami
- Department of Periodontology, Osaka University Graduate School of Dentistry, Suita, Osaka, Japan
| |
Collapse
|
8
|
Senan S, Özgüroğlu M, Daniel D, Villegas A, Vicente D, Murakami S, Hui R, Faivre-Finn C, Paz-Ares L, Wu YL, Mann H, Dennis PA, Antonia SJ. Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial. ESMO Open 2022; 7:100410. [PMID: 35247871 PMCID: PMC9058904 DOI: 10.1016/j.esmoop.2022.100410] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2021] [Revised: 01/11/2022] [Accepted: 01/22/2022] [Indexed: 12/25/2022] Open
Abstract
Background The phase III PACIFIC trial (NCT02125461) established consolidation durvalumab as standard of care for patients with unresectable, stage III non-small-cell lung cancer (NSCLC) and no disease progression following chemoradiotherapy (CRT). In some cases, patients with stage IIIA-N2 NSCLC are considered operable, but the relative benefit of surgery is unclear. We report a post hoc, exploratory analysis of clinical outcomes in the PACIFIC trial, in patients with or without stage IIIA-N2 NSCLC. Materials and methods Patients with unresectable, stage III NSCLC and no disease progression after ≥2 cycles of platinum-based, concurrent CRT were randomized 2 : 1 to receive durvalumab (10 mg/kg intravenously; once every 2 weeks for up to 12 months) or placebo, 1-42 days after CRT. The primary endpoints were progression-free survival (PFS; assessed by blinded independent central review according to RECIST version 1.1) and overall survival (OS). Treatment effects within subgroups were estimated by hazard ratios (HRs) from unstratified Cox proportional hazards models. Results Of 713 randomized patients, 287 (40%) had stage IIIA-N2 disease. Baseline characteristics were similar between patients with and without stage IIIA-N2 NSCLC. With a median follow-up of 14.5 months (range: 0.2-29.9 months), PFS was improved with durvalumab versus placebo in both patients with [HR = 0.46; 95% confidence interval (CI), 0.33-0.65] and without (HR = 0.62; 95% CI 0.48-0.80) stage IIIA-N2 disease. Similarly, with a median follow-up of 25.2 months (range: 0.2-43.1 months), OS was improved with durvalumab versus placebo in patients with (HR = 0.56; 95% CI 0.39-0.79) or without (HR = 0.78; 95% CI 0.57-1.06) stage IIIA-N2 disease. Durvalumab had a manageable safety profile irrespective of stage IIIA-N2 status. Conclusions Consistent with the intent-to-treat population, treatment benefits with durvalumab were confirmed in patients with stage IIIA-N2, unresectable NSCLC. Prospective studies are needed to determine the optimal treatment approach for patients who are deemed operable. The PACIFIC trial established durvalumab after CRT as standard of care for unresectable, stage III NSCLC. The optimum multimodal treatment strategy for patients with potentially resectable, stage IIIA-N2 NSCLC is unknown. Survival benefit with durvalumab was observed in patients with stage IIIA-N2, unresectable NSCLC in this post hoc analysis. Durvalumab after CRT also exhibited a manageable safety profile in this subpopulation from PACIFIC. Studies of surgical vs. non-surgical strategies are needed to establish the best approach for potentially operable patients.
Collapse
Affiliation(s)
- S Senan
- Department of Radiation Oncology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands.
| | - M Özgüroğlu
- Istanbul University-Cerrahpaşa, Cerrahpaşa School of Medicine, Istanbul, Turkey
| | - D Daniel
- Tennessee Oncology, Chattanooga, USA; Sarah Cannon Research Institute, Nashville, USA
| | - A Villegas
- Cancer Specialists of North Florida, Jacksonville, USA
| | - D Vicente
- Hospital Universitario Virgen Macarena, Seville, Spain
| | | | - R Hui
- Westmead Hospital and the University of Sydney, Sydney, Australia
| | - C Faivre-Finn
- The University of Manchester and The Christie NHS Foundation Trust, Manchester, UK
| | - L Paz-Ares
- Universidad Complutense, CiberOnc, CNIO and Hospital Universitario 12 de Octubre, Madrid, Spain
| | - Y L Wu
- Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
| | - H Mann
- AstraZeneca, Cambridge, UK
| | | | - S J Antonia
- H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA
| |
Collapse
|
9
|
Li H, Zhang TT, Said A, Fabbris G, Mazzone DG, Yan JQ, Mandrus D, Halász GB, Okamoto S, Murakami S, Dean MPM, Lee HN, Miao H. Giant phonon anomalies in the proximate Kitaev quantum spin liquid α-RuCl 3. Nat Commun 2021; 12:3513. [PMID: 34112804 PMCID: PMC8192767 DOI: 10.1038/s41467-021-23826-1] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2021] [Accepted: 04/30/2021] [Indexed: 11/18/2022] Open
Abstract
The Kitaev quantum spin liquid epitomizes an entangled topological state, for which two flavors of fractionalized low-energy excitations are predicted: the itinerant Majorana fermion and the Z2 gauge flux. It was proposed recently that fingerprints of fractional excitations are encoded in the phonon spectra of Kitaev quantum spin liquids through a novel fractional-excitation-phonon coupling. Here, we detect anomalous phonon effects in α-RuCl3 using inelastic X-ray scattering with meV resolution. At high temperature, we discover interlaced optical phonons intercepting a transverse acoustic phonon between 3 and 7 meV. Upon decreasing temperature, the optical phonons display a large intensity enhancement near the Kitaev energy, JK~8 meV, that coincides with a giant acoustic phonon softening near the Z2 gauge flux energy scale. These phonon anomalies signify the coupling of phonon and Kitaev magnetic excitations in α-RuCl3 and demonstrates a proof-of-principle method to detect anomalous excitations in topological quantum materials.
Collapse
Affiliation(s)
- Haoxiang Li
- Materials Science and Technology Division, Oak Ridge National Laboratory, Oak Ridge, TN, USA
| | - T T Zhang
- Department of Physics, Tokyo Institute of Technology, Okayama, Meguro-ku, Tokyo, Japan
- Tokodai Institute for Element Strategy, Tokyo Institute of Technology, Nagatsuta, Midori-ku, Yokohama, Kanagawa, Japan
| | - A Said
- Advanced Photon Source, Argonne National Laboratory, Argonne, IL, USA
| | - G Fabbris
- Advanced Photon Source, Argonne National Laboratory, Argonne, IL, USA
| | - D G Mazzone
- Condensed Matter Physics and Materials Science Department, Brookhaven National Laboratory, Upton, NY, USA
- Laboratory for Neutron Scattering and Imaging, Paul Scherrer Institut, Villigen, Switzerland
| | - J Q Yan
- Materials Science and Technology Division, Oak Ridge National Laboratory, Oak Ridge, TN, USA
| | - D Mandrus
- Materials Science and Technology Division, Oak Ridge National Laboratory, Oak Ridge, TN, USA
- Department of Materials Science and Engineering, the University of Tennessee at Knoxville, Knoxville, TN, USA
| | - Gábor B Halász
- Materials Science and Technology Division, Oak Ridge National Laboratory, Oak Ridge, TN, USA
| | - S Okamoto
- Materials Science and Technology Division, Oak Ridge National Laboratory, Oak Ridge, TN, USA
| | - S Murakami
- Department of Physics, Tokyo Institute of Technology, Okayama, Meguro-ku, Tokyo, Japan
- Tokodai Institute for Element Strategy, Tokyo Institute of Technology, Nagatsuta, Midori-ku, Yokohama, Kanagawa, Japan
| | - M P M Dean
- Condensed Matter Physics and Materials Science Department, Brookhaven National Laboratory, Upton, NY, USA
| | - H N Lee
- Materials Science and Technology Division, Oak Ridge National Laboratory, Oak Ridge, TN, USA
| | - H Miao
- Materials Science and Technology Division, Oak Ridge National Laboratory, Oak Ridge, TN, USA.
| |
Collapse
|
10
|
Hanada K, Yoshida N, Hasegawa M, Oya M, Oya Y, Takagi I, Hatayama A, Shikama T, Idei H, Nagashima Y, Ikezoe R, Onchi T, Kuroda K, Kawasaki S, Higashijima A, Nagata T, Shimabukuro S, Nakamura K, Murakami S, Takase Y, Gao X, Liu H, Qian J. Overview of recent progress on steady state operation of all-metal plasma facing wall device QUEST. Nuclear Materials and Energy 2021. [DOI: 10.1016/j.nme.2021.101013] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
11
|
Hasegawa H, Kono T, Sakane K, Matsuoka T, Soyama A, Murakami S, Hoshiga M. Increased oxygen uptake and utilization in the peripheral muscles, rather than cardiac function reserve, may be determinants of increased peak VO2 by cardiac rehabilitation in heart failure. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Peak oxygen consumption (peak VO2) is a major prognostic parameter in heart failure (HF). Previous studies have shown a relationship between peak VO2 and impaired oxygen uptake and utilization in the peripheral muscles. The purpose of this study was to clarify the determinant of increased peak VO2 by cardiac rehabilitation (CR) in patients with HF.
Methods
We performed echocardiography during upright ramp bicycle cardiopulmonary exercise test in 30 HF patients (61±1 years of age, 80% male) before and 6 months after CR. HR reserve was determined as the change in HR from rest to peak exercise, expressed as a percentage of the predicted maximal HR reserve. Elastance index (EAI) and LV end-systolic elastance index (ELVI) were derived as the ratio of end-systolic pressure to stroke volume index and end-systolic volume index, respectively. End-systolic pressure was estimated from the equation 0.9 × brachial systolic blood pressure. Ventriculo-arterial coupling (VAC) was calculated as the quotient of EAI and ELVI. The ratio of LDEDVI to E/e' mean was used to evaluate LV diastolic compliance. Systemic vascular resistance index was calculated as mean arterial pressure divided by echocardiography calculated cardiac index and multiplied by 80. The arterial venous oxygen content difference (C (A-V) O2 gradient) was calculated by using the Fick equation as: VO2/echocardiography calculated cardiac output.
Results
Peak VO2 and C (A-V) O2 gradient were increased by CR. However, heart rate reserve, systolic reserve, VAC, diastolic reserve and vasodilation reserve were unchanged by CR (Table 1).
Conclusions
Increased oxygen uptake and utilization in the peripheral muscles, rather than cardiac function reserve, may be determinants of increased peak VO2 by CR in HF.
Table 1
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
| | - T Kono
- Soseikai General Hospital, Cardiology, Kyoto, Japan
| | - K Sakane
- Osaka Medical College, Takatsuki, Japan
| | - T Matsuoka
- Soseikai General Hospital, Cardiology, Kyoto, Japan
| | - A Soyama
- Soseikai General Hospital, Cardiology, Kyoto, Japan
| | - S Murakami
- Soseikai General Hospital, Cardiology, Kyoto, Japan
| | - M Hoshiga
- Osaka Medical College, Takatsuki, Japan
| |
Collapse
|
12
|
Isobe W, Murakami S, Saito T, Kumagai S, Sakita M. Effect of aerobic exercise on muscle structure and expression of proteins promoting hypertrophy and metabolism in aged rats. Comparative Exercise Physiology 2020. [DOI: 10.3920/cep190077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Aging and physical inactivity lead to histochemical changes in muscles. The expression of many muscle proteins, including brain-derived neurotrophic factor (BDNF), silent information regulator of transcription 1 (SIRT1), and peroxisome proliferator-activated receptor γγ coactivator-1α (PGC-1a), declines with age. However, the effect of aerobic exercise on muscle structure and the expression profile of these proteins in elderly rats is unknown. Here, we investigated whether short-term aerobic exercise improves muscle structure and increases BDNF, SIRT1, and PGC-1a levels in aged rats. Ten male Wistar rats (95-week-old) were assigned to sedentary (SED) or exercise (Ex) groups. The Ex group performed running on a treadmill for 1 h, 6 times per week, for 2 weeks. The extensor digitorum longus muscles were removed to examine the muscle fibre type composition, cross-sectional area, and capillary-to-fibre (C/F) ratio. BDNF, SIRT1, and PGC-1a levels were evaluated by western blotting. Relative to the SED group, the Ex group showed increased proportion of Type I fibres (P<0.05), cross-sectional area of all muscle fibre types (P<0.05), succinate dehydrogenase activity (P<0.001), C/F ratio (P<0.05), and expression of BDNF, SIRT1, and PGC-1a (P<0.05).Thus, 2 weeks of aerobic exercise is sufficient to improve muscle histology and hypertrophic marker protein expression, indicating that it could prevent skeletal muscle atrophy in elderly rats.
Collapse
Affiliation(s)
- W. Isobe
- Course in Physical Therapy, Graduate School of Health Sciences, Kyoto Tachibana University, 34 Oyakeyamada, Yamashina Ward, Kyoto City, Kyoto 607-8175, Japan
- Department of Rehabilitation, Mitsubishi Kyoto Hospital, 1 Katsuragosho, Nishikyo Ward, Kyoto City, Kyoto 615-8087, Japan
| | - S. Murakami
- Department of Physical Therapy, Faculty of Health Care Sciences, Himeji-Dokkyo University, 7-2-1 Kamiono, Himeji City, Hyogo 670-0896, Japan
| | - T. Saito
- Department of Physical Therapy, Aso Rehabilitation College, 3-2-1 Higashi-hie, Hakata Ward, Fukuoka 812-0007, Japan
| | - S. Kumagai
- Laboratory of Health and Exercise Epidemiology, Center for Health Science and Counseling, Kyushu University, 744 Motoka, Nishi Ward, Fukuoka City, Fukuoka 819-0395, Japan
| | - M. Sakita
- Graduate school of Health Sciences, Kyoto Tachibana University, 34 Oyakeyamada, Yamashina Ward, Kyoto City, Kyoto 607-8175, Japan
| |
Collapse
|
13
|
Tai K, Komatsu S, Sofue K, Kido M, Tanaka M, Kuramitsu K, Awazu M, Gon H, Tsugawa D, Yanagimoto H, Toyama H, Murakami S, Murakami T, Fukumoto T. Total tumour volume as a prognostic factor in patients with resectable colorectal cancer liver metastases. BJS Open 2020; 4:456-466. [PMID: 32277807 PMCID: PMC7260417 DOI: 10.1002/bjs5.50280] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2020] [Accepted: 02/16/2020] [Indexed: 12/29/2022] Open
Abstract
Background Although total tumour volume (TTV) may have prognostic value for hepatic resection in certain solid cancers, its importance in colorectal liver metastases (CRLM) remains unexplored. This study investigated its prognostic value in patients with resectable
CRLM. Method This was a retrospective review of patients who underwent hepatic resection for CRLM between 2008 and 2017 in a single institution. TTV was measured from CT images using three‐dimensional construction software; cut‐off values were determined using receiver operating characteristic (ROC) curve analyses. Potential prognostic factors, overall survival (OS) and recurrence‐free survival (RFS) were determined using multivariable and Kaplan–Meier analyses. Results Some 94 patients were included. TTV cut‐off values for OS and RFS were 100 and 10 ml respectively. Right colonic primary tumours, primary lymph node metastasis and bilobar liver metastasis were included in the multivariable analysis of OS; a TTV of 100 ml or above was independently associated with poorer OS (hazard ratio (HR) 6·34, 95 per cent c.i. 2·08 to 17·90; P = 0·002). Right colonic primary tumours and primary lymph node metastasis were included in the RFS analysis; a TTV of 10 ml or more independently predicted poorer RFS (HR 1·90, 1·12 to 3·57; P = 0·017). The 5‐year OS rate for a TTV of 100 ml or more was 41 per cent, compared with 67 per cent for a TTV below 100 ml (P = 0·006). Corresponding RFS rates with TTV of 10 ml or more, or less than 10 ml, were 14 and 58 per cent respectively (P = 0·009). A TTV of at least 100 ml conferred a higher rate of unresectable initial recurrences (12 of 15, 80 per cent) after initial hepatic resection. Conclusion TTV was associated with RFS and OS after initial hepatic resection for CRLM; TTV of 100 ml or above was associated with a higher rate of unresectable recurrence.
Collapse
Affiliation(s)
- K Tai
- Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe, Hyogo, Japan
| | - S Komatsu
- Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe, Hyogo, Japan
| | - K Sofue
- Department of Radiology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
| | - M Kido
- Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe, Hyogo, Japan
| | - M Tanaka
- Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe, Hyogo, Japan
| | - K Kuramitsu
- Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe, Hyogo, Japan
| | - M Awazu
- Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe, Hyogo, Japan
| | - H Gon
- Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe, Hyogo, Japan
| | - D Tsugawa
- Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe, Hyogo, Japan
| | - H Yanagimoto
- Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe, Hyogo, Japan
| | - H Toyama
- Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe, Hyogo, Japan
| | - S Murakami
- Clinical and Translational Research Centre, Kobe University Hospital, Kobe, Hyogo, Japan
| | - T Murakami
- Department of Radiology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
| | - T Fukumoto
- Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe, Hyogo, Japan
| |
Collapse
|
14
|
Sakano M, Hirayama M, Takahashi T, Akebi S, Nakayama M, Kuroda K, Taguchi K, Yoshikawa T, Miyamoto K, Okuda T, Ono K, Kumigashira H, Ideue T, Iwasa Y, Mitsuishi N, Ishizaka K, Shin S, Miyake T, Murakami S, Sasagawa T, Kondo T. Radial Spin Texture in Elemental Tellurium with Chiral Crystal Structure. Phys Rev Lett 2020; 124:136404. [PMID: 32302163 DOI: 10.1103/physrevlett.124.136404] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/21/2019] [Accepted: 02/10/2020] [Indexed: 06/11/2023]
Abstract
The chiral crystal is characterized by a lack of mirror symmetry and inversion center, resulting in the inequivalent right- and left-handed structures. In the noncentrosymmetric crystal structure, the spin and momentum of electrons are expected to be locked in the reciprocal space with the help of the spin-orbit interaction. To reveal the spin textures of chiral crystals, we investigate the spin and electronic structure in a p-type semiconductor, elemental tellurium, with the simplest chiral structure by using spin- and angle-resolved photoemission spectroscopy. Our data demonstrate that the highest valence band crossing the Fermi level has a spin component parallel to the electron momentum around the Brillouin zone corners. Significantly, we have also confirmed that the spin polarization is reversed in the crystal with the opposite chirality. The results indicate that the spin textures of the right- and left-handed chiral crystals are hedgehoglike, leading to unconventional magnetoelectric effects and nonreciprocal phenomena.
Collapse
Affiliation(s)
- M Sakano
- Institute for Solid State Physics (ISSP), The University of Tokyo, Kashiwa 277-8581, Japan
- Quantum-Phase Electronics Center (QPEC) and Department of Applied Physics, The University of Tokyo, Bunkyo-ku, Tokyo 113-8656, Japan
| | - M Hirayama
- Department of Physics, Tokyo Institute of Technology, Meguro-ku, Tokyo 152-8551, Japan
- Tokodai Institute for Element Strategy (TIES), Tokyo Institute of Technology, Meguro-ku, Tokyo 152-8551, Japan
- RIKEN Center for Emergent Matter Science (CEMS), Wako, Saitama 351-0198, Japan
| | - T Takahashi
- Materials and Structures Laboratory (MSL), Tokyo Institute of Technology, Yokohama, Kanagawa 226-8503, Japan
| | - S Akebi
- Institute for Solid State Physics (ISSP), The University of Tokyo, Kashiwa 277-8581, Japan
| | - M Nakayama
- Institute for Solid State Physics (ISSP), The University of Tokyo, Kashiwa 277-8581, Japan
| | - K Kuroda
- Institute for Solid State Physics (ISSP), The University of Tokyo, Kashiwa 277-8581, Japan
| | - K Taguchi
- Graduate School of Science, Hiroshima University, Higashi-Hiroshima, Hiroshima 739-8526, Japan
| | - T Yoshikawa
- Graduate School of Science, Hiroshima University, Higashi-Hiroshima, Hiroshima 739-8526, Japan
| | - K Miyamoto
- Hiroshima Synchrotron Radiation Center (HiSOR), Hiroshima University, Higashi-Hiroshima, Hiroshima 739-0046, Japan
| | - T Okuda
- Hiroshima Synchrotron Radiation Center (HiSOR), Hiroshima University, Higashi-Hiroshima, Hiroshima 739-0046, Japan
| | - K Ono
- Institute of Materials Structure Science, High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - H Kumigashira
- Institute of Materials Structure Science, High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
- Institute of Multidisciplinary Research for Advanced Materials (IMRAM), Tohoku University, Sendai 980-8577, Japan
| | - T Ideue
- Quantum-Phase Electronics Center (QPEC) and Department of Applied Physics, The University of Tokyo, Bunkyo-ku, Tokyo 113-8656, Japan
| | - Y Iwasa
- Quantum-Phase Electronics Center (QPEC) and Department of Applied Physics, The University of Tokyo, Bunkyo-ku, Tokyo 113-8656, Japan
- RIKEN Center for Emergent Matter Science (CEMS), Wako, Saitama 351-0198, Japan
| | - N Mitsuishi
- Quantum-Phase Electronics Center (QPEC) and Department of Applied Physics, The University of Tokyo, Bunkyo-ku, Tokyo 113-8656, Japan
| | - K Ishizaka
- Quantum-Phase Electronics Center (QPEC) and Department of Applied Physics, The University of Tokyo, Bunkyo-ku, Tokyo 113-8656, Japan
- RIKEN Center for Emergent Matter Science (CEMS), Wako, Saitama 351-0198, Japan
| | - S Shin
- Institute for Solid State Physics (ISSP), The University of Tokyo, Kashiwa 277-8581, Japan
| | - T Miyake
- Research Center for Computational Design of Advanced Functional Materials (CD-FMat), AIST, Tsukuba, Ibaraki 305-8568, Japan
| | - S Murakami
- Department of Physics, Tokyo Institute of Technology, Meguro-ku, Tokyo 152-8551, Japan
- Tokodai Institute for Element Strategy (TIES), Tokyo Institute of Technology, Meguro-ku, Tokyo 152-8551, Japan
| | - T Sasagawa
- Materials and Structures Laboratory (MSL), Tokyo Institute of Technology, Yokohama, Kanagawa 226-8503, Japan
| | - Takeshi Kondo
- Institute for Solid State Physics (ISSP), The University of Tokyo, Kashiwa 277-8581, Japan
- AIST-UTokyo Advanced Operando-Measurement Technology Open Innovation Laboratory (OPERANDO-OIL), Kashiwa, Chiba 277-8581, Japan
- Trans-scale Quantum Science Institute, The University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan
| |
Collapse
|
15
|
Paz-Ares L, Spira A, Raben D, Planchard D, Cho BC, Özgüroğlu M, Daniel D, Villegas A, Vicente D, Hui R, Murakami S, Spigel D, Senan S, Langer CJ, Perez BA, Boothman AM, Broadhurst H, Wadsworth C, Dennis PA, Antonia SJ, Faivre-Finn C. Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial. Ann Oncol 2020; 31:798-806. [PMID: 32209338 DOI: 10.1016/j.annonc.2020.03.287] [Citation(s) in RCA: 122] [Impact Index Per Article: 30.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2020] [Accepted: 03/14/2020] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND In the PACIFIC trial, durvalumab significantly improved progression-free and overall survival (PFS/OS) versus placebo, with manageable safety, in unresectable, stage III non-small-cell lung cancer (NSCLC) patients without progression after chemoradiotherapy (CRT). We report exploratory analyses of outcomes by tumour cell (TC) programmed death-ligand 1 (PD-L1) expression. PATIENTS AND METHODS Patients were randomly assigned (2:1) to intravenous durvalumab 10 mg/kg every 2 weeks or placebo ≤12 months, stratified by age, sex, and smoking history, but not PD-L1 status. Where available, pre-CRT samples were tested for PD-L1 expression (immunohistochemistry) and scored at pre-specified (25%) and post hoc (1%) TC cut-offs. Treatment-effect hazard ratios (HRs) were estimated from unstratified Cox proportional hazards models (Kaplan-Meier-estimated medians). RESULTS In total, 713 patients were randomly assigned, 709 of whom received at least 1 dose of study treatment durvalumab (n = 473) or placebo (n = 236). Some 451 (63%) were PD-L1-assessable: 35%, 65%, 67%, 33%, and 32% had TC ≥25%, <25%, ≥1%, <1%, and 1%-24%, respectively. As of 31 January 2019, median follow-up was 33.3 months. Durvalumab improved PFS versus placebo (primary-analysis data cut-off, 13 February 2017) across all subgroups [HR, 95% confidence interval (CI); medians]: TC ≥25% (0.41, 0.26-0.65; 17.8 versus 3.7 months), <25% (0.59, 0.43-0.82; 16.9 versus 6.9 months), ≥1% (0.46, 0.33-0.64; 17.8 versus 5.6 months), <1% (0.73, 0.48-1.11; 10.7 versus 5.6 months), 1%-24% [0.49, 0.30-0.80; not reached (NR) versus 9.0 months], and unknown (0.59, 0.42-0.83; 14.0 versus 6.4 months). Durvalumab improved OS across most subgroups (31 January 2019 data cut-off; HR, 95% CI; medians): TC ≥ 25% (0.50, 0.30-0.83; NR versus 21.1 months), <25% (0.89, 0.63-1.25; 39.7 versus 37.4 months), ≥1% (0.59, 0.41-0.83; NR versus 29.6 months), 1%-24% (0.67, 0.41-1.10; 43.3 versus 30.5 months), and unknown (0.60, 0.43-0.84; 44.2 versus 23.5 months), but not <1% (1.14, 0.71-1.84; 33.1 versus 45.6 months). Safety was similar across subgroups. CONCLUSIONS PFS benefit with durvalumab was observed across all subgroups, and OS benefit across all but TC <1%, for which limitations and wide HR CI preclude robust conclusions.
Collapse
Affiliation(s)
- L Paz-Ares
- Hospital Universitario 12 de Octubre, Lung Cancer Unit CNIO-H12o, CiberOnc and Universidad Complutense, Madrid, Spain.
| | - A Spira
- Virginia Health Specialists, Fairfax, USA
| | - D Raben
- Department of Radiation Oncology, University of Colorado Denver, Aurora, USA
| | - D Planchard
- Gustave Roussy, Department of Medical Oncology, Thoracic Unit, Villejuif, France
| | - B C Cho
- Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea
| | - M Özgüroğlu
- Istanbul University - Cerrahpaşa, Cerrahpaşa School of Medicine, Istanbul, Turkey
| | - D Daniel
- Tennessee Oncology, Chattanooga and Sarah Cannon Research Institute, Nashville, USA
| | - A Villegas
- Cancer Specialists of North Florida, Jacksonville, USA
| | - D Vicente
- Department of Clinical Oncology, H.U.V. Macarena, Seville, Spain
| | - R Hui
- Westmead Hospital and University of Sydney, Sydney, Australia
| | | | - D Spigel
- Tennessee Oncology, Chattanooga and Sarah Cannon Research Institute, Nashville, USA
| | - S Senan
- Department of Radiation Oncology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands
| | - C J Langer
- Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA
| | - B A Perez
- H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA
| | | | | | | | | | - S J Antonia
- H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA
| | - C Faivre-Finn
- The University of Manchester and The Christie NHS Foundation Trust, Manchester, UK
| |
Collapse
|
16
|
Kubo T, Nogami N, Bessho A, Morita A, Ikeo S, Yokoyama T, Ishihara M, Honda T, Fujimoto N, Murakami S, Kaira K, Harada T, Nakamura K, Iwasawa S, Shimokawa T, Kiura K, Yamashita N, Okamoto H. Phase II trial of carboplatin, nab-paclitaxel and bevacizumab for advanced non-squamous non-small cell lung cancer (CARNAVAL study; TORG1424/OLCSG1402). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz437.037] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
17
|
Yamada H, Tanaka K, Seki R, Suzuki C, Ida K, Fujii K, Goto M, Murakami S, Osakabe M, Tokuzawa T, Yokoyama M, Yoshinuma M. Isotope Effect on Energy Confinement Time and Thermal Transport in Neutral-Beam-Heated Stellarator-Heliotron Plasmas. Phys Rev Lett 2019; 123:185001. [PMID: 31763903 DOI: 10.1103/physrevlett.123.185001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/02/2019] [Revised: 08/30/2019] [Indexed: 06/10/2023]
Abstract
The isotope effect on energy confinement time and thermal transport has been investigated for plasmas confined by a stellarator-heliotron magnetic field. This is the first detailed assessment of an isotope effect in a stellarator heliotron. Hydrogen and deuterium plasmas heated by neutral beam injection on the Large Helical Device have exhibited no significant dependence on the isotope mass in thermal energy confinement time, which is not consistent with the simple gyro-Bohm model. A comparison of thermal diffusivity for dimensionally similar hydrogen and deuterium plasmas in terms of the gyroradius, collisionality, and thermal pressure has clearly shown robust confinement improvement in deuterium to compensate for the unfavorable mass dependence predicted by the gyro-Bohm model.
Collapse
Affiliation(s)
- H Yamada
- National Institute for Fusion Science, National Institutes of Natural Sciences, Toki, Gifu 509-5292, Japan
- The University of Tokyo, Kashiwa, Chiba 277-8568, Japan
| | - K Tanaka
- National Institute for Fusion Science, National Institutes of Natural Sciences, Toki, Gifu 509-5292, Japan
- Kyushu University, Kasuga, Fukuoka 816-8580, Japan
| | - R Seki
- National Institute for Fusion Science, National Institutes of Natural Sciences, Toki, Gifu 509-5292, Japan
- SOKENDAI (The Graduate University for Advanced Studies), Toki, Gifu 509-5292, Japan
| | - C Suzuki
- National Institute for Fusion Science, National Institutes of Natural Sciences, Toki, Gifu 509-5292, Japan
| | - K Ida
- National Institute for Fusion Science, National Institutes of Natural Sciences, Toki, Gifu 509-5292, Japan
| | - K Fujii
- Kyoto University, Kyoto 615-8530, Japan
| | - M Goto
- National Institute for Fusion Science, National Institutes of Natural Sciences, Toki, Gifu 509-5292, Japan
- SOKENDAI (The Graduate University for Advanced Studies), Toki, Gifu 509-5292, Japan
| | | | - M Osakabe
- National Institute for Fusion Science, National Institutes of Natural Sciences, Toki, Gifu 509-5292, Japan
- SOKENDAI (The Graduate University for Advanced Studies), Toki, Gifu 509-5292, Japan
| | - T Tokuzawa
- National Institute for Fusion Science, National Institutes of Natural Sciences, Toki, Gifu 509-5292, Japan
- SOKENDAI (The Graduate University for Advanced Studies), Toki, Gifu 509-5292, Japan
| | - M Yokoyama
- National Institute for Fusion Science, National Institutes of Natural Sciences, Toki, Gifu 509-5292, Japan
- SOKENDAI (The Graduate University for Advanced Studies), Toki, Gifu 509-5292, Japan
| | - M Yoshinuma
- National Institute for Fusion Science, National Institutes of Natural Sciences, Toki, Gifu 509-5292, Japan
| |
Collapse
|
18
|
Wu YL, Gray J, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee K, Cho B, Planchard D, Paz-Ares L, Faivre-Finn C, Vansteenkiste J, Spigel D, Taboada M, Dennis P, Özgüroğlu M, Antonia S. Three-year overall survival update from the PACIFIC trial. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz438.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
19
|
Kondo T, Nakahara Y, Usui R, Murakami S, Kato T, Saito H, Yamada K. EP1.01-72 Treatment Outcome of 2nd Generation EGFR-TKI for Non-Small Cell Lung Cancer. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.2045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
20
|
Vansteenkiste J, Naidoo J, Faivre-Finn C, Özgüroğlu M, Villegas A, Daniel D, Murakami S, Hui R, Lee K, Cho B, Kubota K, Taboada M, Wadsworth C, Dennis P, Antonia S. Efficacy of durvalumab in patients with stage III NSCLC who experience pneumonitis (PACIFIC). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz259.002] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
21
|
Murakami S, Seto T, Satouchi M, Nishio M, Hayashi H, Ohe Y, Asato T, Zhang P, Nakagawa K. P1.01-103 Preliminary Results of Brigatinib in Japanese Patients (Pts) Who Previously Received Alectinib: Brigatinib-2001 Study. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.818] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
22
|
Okada A, Ota K, Horimoto K, Ibaraki T, Murakami S, Takenaka H, Choh S. EP1.16-38 Pulmonary Infiltrates in Patients Treated with Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.2403] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
23
|
Idei H, Onchi T, Kariya T, Tsujimura T, Kubo S, Kobayashi S, Sakaguchi M, Imai T, Hasegawa M, Nakamura K, Mishra K, Fukuyama M, Yunoki M, Kojima S, Watanabe O, Kuroda K, Hanada K, Nagashima Y, Ejiri A, Matsumoto N, Ono M, Higashijima A, Nagata T, Shimabukoro S, Takase Y, Fukuyama A, Murakami S. 28-GHz ECHCD system with beam focusing launcher on the QUEST spherical tokamak. Fusion Engineering and Design 2019. [DOI: 10.1016/j.fusengdes.2019.02.027] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
24
|
Ida K, Yoshinuma M, Yamasaki K, Kobayashi T, Fujiwara Y, Chen J, Murakami I, Satake S, Yamamoto Y, Murakami S, Kobayashi M. Measurements of radial profile of hydrogen and deuterium density in isotope mixture plasmas using bulk charge exchange spectroscopy. Rev Sci Instrum 2019; 90:093503. [PMID: 31575284 DOI: 10.1063/1.5097030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/22/2019] [Accepted: 08/17/2019] [Indexed: 06/10/2023]
Abstract
A bulk charge exchange spectroscopy system has been applied to measure the radial profiles of the hydrogen (H) and deuterium (D) density ratio in the isotope mixture plasma in a large helical device. Charge exchange lines of Hα and Dα are fitted by 4 Gaussian of H and D cold components and H and D hot components with 5 parameters by combining the measurement of plasma toroidal rotation velocity with carbon charge exchange spectroscopy. The radial profiles of the relative density of hydrogen and deuterium ions are derived from H and D hot components measured and the beam density calculated from beam attenuation calculation. A proof-of-principle experiment is performed by the H pellet and the D pellet injections into the H-D mixture plasma.
Collapse
Affiliation(s)
- K Ida
- National Institute for Fusion Science, National Institutes of Natural Sciences, Toki, Gifu 509-5292, Japan
| | - M Yoshinuma
- National Institute for Fusion Science, National Institutes of Natural Sciences, Toki, Gifu 509-5292, Japan
| | - K Yamasaki
- Research Institute for Applied Mechanics Kyushu University, Kasuga, Fukuoka, Japan
| | - T Kobayashi
- National Institute for Fusion Science, National Institutes of Natural Sciences, Toki, Gifu 509-5292, Japan
| | - Y Fujiwara
- National Institute for Fusion Science, National Institutes of Natural Sciences, Toki, Gifu 509-5292, Japan
| | - J Chen
- School of Nuclear Science and Technology, University of Science and Technology of China, Hefei 230026, China
| | - I Murakami
- National Institute for Fusion Science, National Institutes of Natural Sciences, Toki, Gifu 509-5292, Japan
| | - S Satake
- National Institute for Fusion Science, National Institutes of Natural Sciences, Toki, Gifu 509-5292, Japan
| | - Y Yamamoto
- Department of Nuclear Engineering, Kyoto University, Kyoto 615-8450, Japan
| | - S Murakami
- Department of Nuclear Engineering, Kyoto University, Kyoto 615-8450, Japan
| | - M Kobayashi
- National Institute for Fusion Science, National Institutes of Natural Sciences, Toki, Gifu 509-5292, Japan
| |
Collapse
|
25
|
Affiliation(s)
- Y Tomoda
- Department of General Medicine, Saiseikai Fukuoka General Hospital, 1-3-46, Tenjin, Chuo-ku, Fukuoka, Fukuoka
| | - S Murakami
- Department of Surgery, National Hospital Organization Saga Hospital, 1-20-1, Hinode, Saga, Saga
| | - K Kawaguchi
- Department of Pulmonary Medicine, Kure Kyosai Hospital, 2-3-28, Nishi-chuo, Kure, Hiroshima
| | - T Orihashi
- Department of Pulmonary Medicine, Kitakyushu General Hospital, 1-1, Higashijono, Kokurakita-ku, Kitakyushu, Fukuoka, Japan
| | - K Tanaka
- Department of General Medicine, Saiseikai Fukuoka General Hospital, 1-3-46, Tenjin, Chuo-ku, Fukuoka, Fukuoka
| |
Collapse
|
26
|
Garassino M, Paz-Ares L, Hui R, Faivre-Finn C, Spira A, Planchard D, Ozguroglu M, Daniel D, Vicente D, Murakami S, Rydén A, Zhang Y, O’Brien C, Dennis P, Antonia S. Patient-reported outcomes (PROs) with durvalumab by PD-L1 expression in unresectable, stage III NSCLC (PACIFIC). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz094.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
27
|
Vasquez YM, Setlem R, Murakami S, Kraus WL. Abstract P5-05-16: Role of estrogen receptor alpha acetylation in estrogen-dependent gene regulation in breast cancers. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p5-05-16] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Estrogens, such as 17β-estradiol (E2), act through estrogen receptor alpha (ERα), a ligand-regulated transcription factor that binds across the genome to promote enhancer formation and regulate gene expression. ERα is expressed in approximately 70% of breast cancers, where it regulates the transcription of genes involved in mitogenic and inflammatory pathways. We are exploring the the acetylation of ERα on lysines 266 and 268, a modification that enhances the DNA binding and transcriptional activities of ERα. ERα acetylation is catalyzed by the lysine acetyltransferases p300 and CBP in an E2- and steroid receptor coregulator (SRC)-dependent manner. Acetylation-dependent activation of ERα has potential implications in breast cancers associated with enhanced coregulator interactions, such as SRC-3/Amplified in Breast (AIB1) gene amplifications and gain-of-function ERα mutations in endocrine resistant metastatic tumors, such as Y537S and D538G. Increased association of ERα with SRCs and p300/CBP leading to enhanced ERα acetylation may promote gain-of-function ERα activity. Our hypothesis is that acetylation of ERα alters its function by increasing E2-responsive gene transcription and signaling in breast cancers. Our current efforts are focused on investigating the role of ERα acetylation on chromatin binding and accessibility, enhancer activity, and target gene transcription. We are using the ER-positive MCF-7 breast cancer cell line with a knockdown/re-expression strategy with biochemical mimics of acetylated (K266/268Q) or unacetylated (K266/268R) ERα. Genomic ERα binding profiles using chromatin immunoprecipitation-sequencing (ChIP-seq) has defined overlapping, but unique, sets of transcriptional targets and recruitment kinetics for the ERα mutants. Current efforts are focused on defining global transcriptional responses associated with the unique binding activities using precision run-on sequencing (PRO-seq). Ultimately, our goal is to define how acetylation affects the binding of ERα to chromatin and its effect on the transcriptional activity of E2-target genes in breast cancers in the context of gain-of-function ERα mutations and coregulator amplifications. Supported in part by a postdoctoral fellowship from the Lalor Foundation to YMV, and grants from the NIDDK, NICHD, and CPRIT to WLK, as well as support from the Cecil H. and Ida Green Center for Reproductive Biology Sciences Endowment.
Citation Format: Vasquez YM, Setlem R, Murakami S, Kraus WL. Role of estrogen receptor alpha acetylation in estrogen-dependent gene regulation in breast cancers [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-05-16.
Collapse
Affiliation(s)
- YM Vasquez
- UT Southwestern Medical Center, Dallas, TX
| | - R Setlem
- UT Southwestern Medical Center, Dallas, TX
| | - S Murakami
- UT Southwestern Medical Center, Dallas, TX
| | - WL Kraus
- UT Southwestern Medical Center, Dallas, TX
| |
Collapse
|
28
|
Raben D, Faivre-Finn C, Spigel D, Daniel D, Villegas A, Vincente D, Hui R, de Castro Carpeno J, Murakami S, Paz-Ares L, Özgüroğlu M, Kurata T, Chiappori A, Lee K, de Wit M, Poole L, Wadsworth C, Dennis P, Antonia S. PACIFIC: Overall Survival with Durvalumab versus Placebo after Chemoradiotherapy in Stage III NSCLC. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.08.057] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
29
|
Mizuno T, Horinouchi H, Watanabe S, Sato J, Morita R, Matsumoto Y, Murakami S, Goto Y, Kanda S, Fujiwara Y, Yamamoto N, Ohe Y. OA04 Factors Influencing the Non-Administration of Chemotherapies in Patients Who Progressed After First-Line EGFR-TKIs. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.10.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
30
|
Jo H, Horinouchi H, Higashiyama R, Tamura N, Yagishita S, Matsumoto Y, Murakami S, Goto Y, Kanda S, Fujiwara Y, Yamamoto N, Ohe Y. P023 Factors Associated With Administration of Subsequent Cytotoxic Chemotherapy after Nivolumab in Patients With Advanced NSCLC. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.10.047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
31
|
Watanabe J, Horinouchi H, Shinno Y, Murakami S, Goto Y, Kanda S, Fujiwara Y, Yamamoto N, Nakamura Y, Watanabe S, Ohe Y. P050 Long-Term Survival of Stage IIIA-N2 NSCLC Patients with Interstitial Lung Diseases. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.10.072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
32
|
Makihara R, Narita S, Yamamoto N, Sato J, Murakami S, Goto Y, Kanda S, Fujiwara Y, Horinouchi H, Tsukamoto T, Hashimoto H, Makino Y, Ohe Y, Yamaguchi M. Relationships between lenvatinib plasma concentration and toxicity in Japanese cancer patients. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy430.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
33
|
Damiani C, Palmer J, Takeda N, Annino C, Balagué S, Bates P, Bernal S, Cornellá J, Dubus G, Esqué S, Gonzalez C, Ilkei T, Lewczanin M, Locke D, Mont L, Perrier B, Puiu A, Ruiz E, Shuff R, Van De Ven N, Van Hille C, Van Uffelen M, Choi C, Friconneau J, Hamilton D, Martin J, Murakami S, Reichle R, Cuevas JS, Maruyama T, Noguchi Y, Saito M. Overview of the ITER remote maintenance design and of the development activities in Europe. Fusion Engineering and Design 2018. [DOI: 10.1016/j.fusengdes.2018.04.085] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
34
|
Shinno Y, Kanda S, Sato J, Morita R, Matsumoto Y, Murakami S, Goto Y, Horinouchi H, Fujiwara Y, Yamamoto N, Ohe Y. Clinical courses of patients with small cell lung cancer after complete resection followed by adjuvant chemotherapy. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy445.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
35
|
Murakami S. COMPARATIVE BIOLOGICAL ANALYSIS OF DEMENTIA RISK FACTOR GENES FOR HUMANS AND CAENORHABDITIS ELEGANS. Innov Aging 2018. [DOI: 10.1093/geroni/igy023.367] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
36
|
Shibaki R, Murakami S, Matsumoto Y, Goto Y, Kanda S, Horinouchi H, Fujiwara Y, Yamamoto N, Ohe Y. Association of immune-related pneumonitis with the phenotypic appearance of concurrent ILD in patients treated with anti-PD-1 antibody. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy425.045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
37
|
Takeyasu Y, Goto Y, Morita R, Sato J, Murakami S, Horinouchi H, Fujiwara Y, Kanda S, Yamamoto N, Ohe Y. Efficacy and safety of epidermal growth factor receptor (EGFR) - Tyrosine kinase inhibitors (TKI) in elderly patients with EGFR mutation-positive non-small cell lung cancer (NSCLC). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy425.030] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
38
|
Spigel D, Vansteenkiste J, Reck M, Wakelee H, Özgüroğlu M, Daniel D, Villegas A, Vicente D, Hui R, Murakami S, Paz-Ares L, Poole L, Wadsworth C, Dennis P, Antonia S. P1.16-05 Effect of Induction Chemotherapy in the PACIFIC Study. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.974] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
|
39
|
Hojo M, Kobayashi N, Hasegawa Y, Sakamoto Y, Murakami S, Yamamoto Y, Tada Y, Maeno A, Kubo Y, Ando H, Shimizu M, Taquahashi Y, Suzuki T, Nakae D, Hirose A. Relationship between developmental toxicity of multi-wall carbon nanotubes and lung inflammation in pregnant mice after repeated intratracheal instillation. Toxicol Lett 2018. [DOI: 10.1016/j.toxlet.2018.06.915] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
40
|
Horinouchi H, Matsumoto Y, Murakami S, Goto Y, Kanda S, Fujiwara Y, Yamamoto N, Nakayama Y, Ohe Y. Optimal interval from preceding radiotherapy (RT) to enhance efficacy of immune check point inhibitors (ICIs): Consecutive analysis of 294 patients with non-small cell lung cancer (NSCLC). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy292.119] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
41
|
Faivre-Finn C, Spigel D, Senan S, Langer C, Raben D, Perez B, Özgüroğlu M, Daniel D, Villegas A, Vicente D, Hui R, Murakami S, Paz-Ares L, Poole L, Wadsworth C, Dennis P, Antonia S. Efficacy and safety evaluation based on time from completion of radiotherapy to randomization with durvalumab or placebo in pts from PACIFIC. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy291] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
42
|
Antonia S, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee K, De Wit M, Cho B, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim Y, Karapetis C, Hiret S, Ostoros G, Kubota K, Gray J, Paz-Ares L, De Castro Carpeño J, Faivre-Finn C, Reck M, Vansteenkiste J, Spigel D, Wadsworth C, Taboada M, Dennis P, Özgüroğlu M. PL02.01 Overall Survival with Durvalumab Versus Placebo After Chemoradiotherapy in Stage III NSCLC: Updated Results from PACIFIC. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.010] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
43
|
Socinski M, Özgüroğlu M, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Gray J, Park K, Vincent M, Perrone F, Poole L, Wadsworth C, Dennis P, Antonia S. P1.16-04 Outcomes of Patients <70 or ≥70 Years of Age in PACIFIC. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.973] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
|
44
|
Hui R, Özgüroğlu M, Villegas A, Daniel D, Vicente D, Murakami S, Rydén A, Zhang Y, Dennis P, Antonia S. 233O Time to deterioration of symptoms with durvalumab in stage III, locally advanced, unresectable NSCLC: Post-hoc analysis of PACIFIC patient-reported outcomes. J Thorac Oncol 2018. [DOI: 10.1016/s1556-0864(18)30401-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
45
|
Murakami S, Ijima H, Ono T, Kawakami K. Development of Co-Culture System of Hepatocytes with Bone Marrow Cells for Expression and Maintenance of Hepatic Functions. Int J Artif Organs 2018; 27:118-26. [PMID: 15061474 DOI: 10.1177/039139880402700207] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
In this study, a co-culture system of hepatocytes and bone marrow cells (BMCs) was developed and characterized for the expression and maintenance of ammonia metabolism and albumin secretion activities. A culture medium supplemented with epidermal growth factor, insulin, L-proline, hydrocortisone and 20 % (v/v) heat-inactivated fetal bovine serum was developed. In addition to adhesive bone marrow cells, the co-existence of non-adhesive bone marrow cells was effective in expressing liver-specific functions for at least 3 weeks. On the other hand, experiments with Transwell in which cultured cells were separated by a semi-permeable membrane, suggested that soluble factors secreted by BMCs are the key components in the functional enhancement of cells. Furthermore, direct contact between hepatocytes and BMCs enhanced the formation of spheroids and the expression of liver specific functions. These results indicate that this co-culture system is promising in, for example, bioartificial liver, regenerative medicine, and liver function simulator applications.
Collapse
Affiliation(s)
- S Murakami
- Department of Chemical Engineering, Faculty of Engineering, Graduate School, Kyushu University, Fukuoka, Japan
| | | | | | | |
Collapse
|
46
|
Antonia S, Villegas A, Daniel D, Baz DV, Murakami S, Hui R, Yokoi T, Chiappori A, Lee K, de Wit M, Cho B, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Jiang H, Huang Y, Dennis P, Özgüroğlu M. PACIFIC: A Double-Blind, Placebo-Controlled Phase 3 Study of Durvalumab as Consolidation Therapy After Chemoradiation in Patients with Locally Advanced, Unresectable Non–Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.09.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
47
|
Tamura N, Horinouchi H, Sekine K, Matsumoto Y, Murakami S, Goto Y, Kanda S, Fujiwara Y, Yamamoto N, Ohe Y. Efficacy of subsequent cytotoxic chemotherapy after nivolumab for patients with advanced non-small cell lung cancer. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx671.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
48
|
Hui R, Özgüroğlu M, Daniel D, Baz D, Murakami S, Yokoi T, Chiappori A, Lee K, De Wit M, Cho BC, Gray J, Rydén A, Viviers L, Poole L, Dennis P, Antonia S. PL 02.02 Patient-Reported Outcomes with Durvalumab after Chemoradiation in Locally Advanced, Unresectable NSCLC: Data from PACIFIC. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.096] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
49
|
Murakami S, Özgüroğlu M, Villegas A, Daniel D, Baz D, Hui R, Yokoi T, Chiappori A, Lee K, de Wit M, Cho B, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Jiang H, Huang Y, Dennis P, Antonia S. PACIFIC: A double-blind, placebo-controlled Phase III study of durvalumab as consolidation therapy after chemoradiation in patients with locally advanced, unresectable NSCLC. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx670] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
50
|
Okada A, Choh S, Nakai T, Ohbayashi C, Kurono Y, Ueda M, Katayama K, Koguchi N, Murakami S, Takenaka H. P2.01-065 Clinico-Radiological and Pathological Evaluation of Lung Adenocarcinoma with Infiltration on the Computed Tomography of the Chest. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1167] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|